Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022
Applied DNA Sciences (NASDAQ: APDN) will report its fiscal 2022 second quarter financial results on May 12, 2022, after market close. The management team will host a conference call at 4:30 p.m. ET to discuss the results, which will also be available via webcast. Applied DNA specializes in enzymatic DNA production, particularly through its LinearDNA platform, which supports various applications including in vitro diagnostics and therapeutic developments. More information can be found on their website.
- Scheduled financial results report may indicate positive performance.
- Continuous innovation in DNA production technology through LinearDNA.
- None.
Conference Call and Webcast Information - Live
Date: |
|
|
Dial in: |
844-887-9402 |
|
412-317-6798 (international) |
||
Hosts: |
Dr. |
|
|
||
Webcast: |
https://services.choruscall.com/mediaframe/webcast.html?webcastid=oxAfF9iN |
Conference Call and Webcast Information - Replay
A telephonic replay of the conference call will be available for one week beginning one hour after the end of the live conference call.
Dial in: |
877-344-7529 |
|
412-317-0088 (international) |
||
Access Code: 8190790 |
||
Webcast: |
https://services.choruscall.com/mediaframe/webcast.html?webcastid=oxAfF9iN |
|
Availability: |
Telephonic replay: until |
About
Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ("PCR")-based manufacturing platform that allows for the large-scale cell-free production of specific DNA sequences.
The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR T therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies.
The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.
Leveraging its deep expertise in nucleic acid-based technologies, the Company has also established safeCircle™, a high-turnkey solution for population-scale COVID-19 testing. safeCircle is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies that increase testing efficiencies and provide for rapid turn-around-times.
Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.
The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under the ticker symbol 'APPDW.'
Applied DNA is a member of the Russell Microcap® Index.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220509005525/en/
Investor Relations:
Web: www.adnas.com
Twitter: @APDN
Source:
FAQ
When will Applied DNA Sciences report its fiscal 2022 Q2 financial results?
What time will the conference call for the financial results be held for APDN?
Where can I find the webcast for Applied DNA Sciences' financial results?
